ALB and lung carcinoma: NAR, combining neutrophil counts and serum albumin count, is a novel and convenient available biomarker for systemic inflammation status and has been proven to be linked to major adverse events, such as aneurysmal subarachnoid hemorrhage and lung cancer [15-23].